
Suptavumab
CAS No. 1629615-23-1
Suptavumab( —— )
Catalog No. M36790 CAS No. 1629615-23-1
Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 499 | Get Quote |
![]() ![]() |
5MG | 820 | Get Quote |
![]() ![]() |
10MG | 1311 | Get Quote |
![]() ![]() |
25MG | 1822 | Get Quote |
![]() ![]() |
50MG | 2548 | Get Quote |
![]() ![]() |
100MG | 3357 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameSuptavumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSuptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.
-
DescriptionSuptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorRSV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1629615-23-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sim?es EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2021 Dec 6;73(11):e4400-e4408. ?
molnova catalog



related products
-
QD 232
QD 232 is a novel quinazolinedione-based redox modulator that potently inhibits Src/FAK and STAT3 phosphorylation.
-
S3I-201
S3I-201 shows potent inhibition of STAT3 DNA-binding activity with IC50 of 86 μM in cell-free assays, and low activity towards STAT1 and STAT5.
-
MMPP
MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.